Ipsen S.A. (IPSEF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ipsen S.A. (IPSEF) with AI Score 53/100 (Hold). Ipsen S. A. is a global biopharmaceutical company focused on specialty care medicines. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Ipsen S.A. (IPSEF) Healthcare & Pipeline Overview
Ipsen S.A. is a global biopharmaceutical company specializing in oncology, neuroscience, and rare diseases. With a diverse portfolio including Somatuline and Dysport, Ipsen addresses unmet medical needs. The company operates in a competitive landscape, balancing innovation with generic drug pressures and regulatory hurdles.
Investment Thesis
Ipsen S.A. presents a compelling investment case based on its diversified portfolio of specialty care medicines and a focus on high-growth therapeutic areas. The company's oncology franchise, driven by products like Cabometyx and Onivyde, offers significant revenue potential. Its neuroscience portfolio, anchored by Dysport, provides a stable revenue stream with expansion opportunities in medical aesthetics. Ipsen's commitment to R&D and strategic collaborations should fuel pipeline growth. However, investors may want to evaluate the risks associated with patent expirations and competition from biosimilars. With a P/E ratio of 28.99 and a dividend yield of 0.90%, Ipsen offers a blend of growth and income. The company's gross margin of 70.6% reflects its pricing power in specialty markets.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $9.36B reflects Ipsen's significant presence in the biopharmaceutical industry.
- P/E ratio of 28.99 indicates investor expectations for future earnings growth.
- Profit Margin of 12.1% demonstrates Ipsen's ability to generate profits from its operations.
- Gross Margin of 70.6% highlights the company's pricing power and efficient cost management.
- Dividend Yield of 0.90% provides a modest income stream for investors.
Competitors & Peers
Strengths
- Diversified product portfolio in specialty care.
- Strong presence in oncology and neuroscience.
- Global sales and marketing network.
- Strategic partnerships and collaborations.
Weaknesses
- Reliance on key products for revenue generation.
- Exposure to patent expirations and generic competition.
- Limited presence in some emerging markets.
- Dependence on third-party manufacturers.
Catalysts
- Clinical trial results for key pipeline candidates in oncology and neuroscience.
- Expansion of Dysport into new medical aesthetic indications.
- Strategic acquisitions and collaborations to enhance product pipeline.
- Penetration of emerging markets with specialty care products.
Risks
- Patent expirations on key products leading to generic competition.
- Regulatory setbacks or delays in drug approvals.
- Pricing pressures from healthcare payers.
- Product liability claims and litigation.
- Economic downturn impacting healthcare spending.
Growth Opportunities
- Expansion of Oncology Portfolio: Ipsen has the opportunity to expand its oncology portfolio through strategic acquisitions and in-house development of novel cancer therapies. The global oncology market is projected to reach $286 billion by 2025, driven by increasing cancer incidence and advancements in targeted therapies. Ipsen can leverage its expertise in neuroendocrine tumors and renal cell carcinoma to capture a larger share of this market. Timeline: Ongoing, with potential for new product launches within the next 3-5 years.
- Growth in Medical Aesthetics: Ipsen can capitalize on the growing demand for medical aesthetics through its Dysport franchise. The global medical aesthetics market is projected to reach $21.8 billion by 2024, driven by increasing disposable incomes and a growing emphasis on appearance. Ipsen can expand its market share by launching new formulations of Dysport and targeting new aesthetic indications. Timeline: Ongoing, with potential for increased revenue contribution within the next 2-3 years.
- Strategic Partnerships and Acquisitions: Ipsen can pursue strategic partnerships and acquisitions to expand its product pipeline and geographic reach. Collaborations with biotech companies can provide access to innovative technologies and novel drug candidates. Acquisitions can add complementary products and strengthen Ipsen's presence in key therapeutic areas. Timeline: Ongoing, with potential for significant impact on long-term growth.
- Emerging Markets Expansion: Ipsen can expand its presence in emerging markets, where there is a growing demand for specialty care medicines. These markets offer significant growth potential due to increasing healthcare spending and a rising prevalence of chronic diseases. Ipsen can leverage its existing infrastructure and partnerships to penetrate these markets. Timeline: Ongoing, with potential for increased revenue contribution within the next 5-7 years.
- Advancements in Rare Disease Therapies: Ipsen can focus on developing and commercializing therapies for rare diseases, which often have limited treatment options and high unmet medical needs. The rare disease market offers attractive pricing and regulatory incentives. Ipsen can leverage its expertise in rare endocrine disorders to develop innovative therapies for other rare diseases. Timeline: Ongoing, with potential for new product launches within the next 3-5 years.
Opportunities
- Expansion of oncology portfolio through acquisitions.
- Growth in medical aesthetics market with Dysport.
- Penetration of emerging markets with specialty care products.
- Development of novel therapies for rare diseases.
Threats
- Increasing competition from generic drug manufacturers.
- Pricing pressures from healthcare payers.
- Regulatory changes and compliance requirements.
- Product liability claims and litigation.
Competitive Advantages
- Proprietary drug formulations with patent protection.
- Established brands with strong market recognition.
- Specialized expertise in specific therapeutic areas.
- Global sales and marketing infrastructure.
- Strategic partnerships and collaborations.
About IPSEF
Founded in 1929 and headquartered in Boulogne-Billancourt, France, Ipsen S.A. has evolved into a global biopharmaceutical company focused on developing and commercializing innovative medicines in specialty care. The company's portfolio includes treatments for oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. Key products include Somatuline, used for neuroendocrine tumors and acromegaly; Decapeptyl, for advanced metastatic prostate cancer; Cabometyx, targeting renal cell and second-line hepatocellular carcinoma; and Onivyde, used in second-line metastatic pancreatic cancer. Ipsen also markets Dysport, a treatment for motor muscular disorders and medical aesthetics. Additionally, Ipsen offers NutropinAq and Increlex for growth-related disorders in children and adolescents. The company's gastroenterology offerings include Smecta, Forlax, and Fortrans/Eziclen, addressing various digestive ailments. Ipsen also provides Tanakan for cognitive disorders. Ipsen has strategic agreements with companies like Debiopharm and Exelixis to expand its product pipeline and market reach. With a global presence and a focus on specialty care, Ipsen aims to address unmet medical needs and improve patient outcomes.
What They Do
- Develops and commercializes pharmaceutical products.
- Focuses on specialty care medicines.
- Offers treatments for oncology, neuroscience, and rare diseases.
- Markets products like Somatuline, Dysport, and Cabometyx.
- Addresses unmet medical needs in specific therapeutic areas.
- Engages in research and development to expand its product pipeline.
- Forms strategic partnerships to enhance its capabilities.
Business Model
- Develops and manufactures specialty pharmaceutical products.
- Markets and sells its products through a global sales network.
- Generates revenue from product sales and licensing agreements.
- Invests in research and development to discover new therapies.
Industry Context
Ipsen operates within the specialty pharmaceutical sector, which is characterized by high R&D costs, stringent regulatory requirements, and intense competition. The market is driven by an aging population, increasing prevalence of chronic diseases, and advancements in biotechnology. The competitive landscape includes major pharmaceutical companies and smaller biotech firms. Ipsen differentiates itself through its focus on specific therapeutic areas and its strategic partnerships. The global pharmaceuticals market is projected to reach $1.7 trillion by 2027, growing at a CAGR of 5-8%.
Key Customers
- Patients with specific medical conditions.
- Healthcare providers who prescribe Ipsen's products.
- Hospitals and clinics that use Ipsen's therapies.
- Pharmacies that dispense Ipsen's medications.
Financials
Chart & Info
Ipsen S.A. (IPSEF) stock price: Price data unavailable
Latest News
-
Ipsen S.A. publishes its 2025 Consolidated Financial Statements
GlobeNewswire · Feb 19, 2026
-
How The Ipsen (ENXTPA:IPN) Story Is Shifting With New Targets And Pipeline Questions
Simply Wall St. · Feb 13, 2026
-
Ipsen SA (IPSEY) Full Year 2025 Earnings Call Highlights: Strong Sales Growth and Strategic ...
GuruFocus.com · Feb 12, 2026
-
Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance
GlobeNewswire · Feb 12, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IPSEF.
Price Targets
Wall Street price target analysis for IPSEF.
MoonshotScore
What does this score mean?
The MoonshotScore rates IPSEF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Ipsen S.A. publishes its 2025 Consolidated Financial Statements
How The Ipsen (ENXTPA:IPN) Story Is Shifting With New Targets And Pipeline Questions
Ipsen SA (IPSEY) Full Year 2025 Earnings Call Highlights: Strong Sales Growth and Strategic ...
Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance
Leadership: David Loew
CEO
David Loew serves as the CEO of Ipsen, bringing extensive experience in the pharmaceutical industry. Prior to joining Ipsen, he held leadership positions at Sanofi, including Executive Vice President and Head of Sanofi Pasteur, the company's vaccines division. He also served as Senior Vice President, Commercial Operations at Sanofi. Loew has a proven track record of driving growth and innovation in the healthcare sector. He holds a Master's degree in Business Administration from IMD Business School in Lausanne, Switzerland.
Track Record: Since becoming CEO of Ipsen, David Loew has focused on strengthening the company's pipeline, expanding its presence in key therapeutic areas, and driving operational efficiency. He has overseen strategic acquisitions and collaborations to enhance Ipsen's portfolio and market reach. Loew has also emphasized innovation and digital transformation to improve patient outcomes and enhance the company's competitiveness.
IPSEF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Ipsen S.A. (IPSEF) may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, increasing the risk associated with investing in these securities. Trading on the OTC Other tier does not guarantee the legitimacy or financial health of the company, and investors should exercise caution and conduct thorough due diligence.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower trading volume can lead to price volatility.
- Potential for manipulation and fraud is higher on the OTC market.
- OTC stocks may be subject to less regulatory oversight.
- Liquidity risk can make it difficult to exit positions.
- Verify the company's registration and regulatory filings.
- Review the company's financials, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any red flags or warning signs.
- Established presence in the biopharmaceutical industry.
- Global sales and marketing network.
- Portfolio of approved pharmaceutical products.
- Strategic partnerships with reputable companies.
- CEO with experience in the pharmaceutical industry.
What Investors Ask About Ipsen S.A. (IPSEF) — Healthcare
What does Ipsen S.A. do?
Ipsen S.A. is a global biopharmaceutical company focused on developing and commercializing innovative medicines in specialty care. The company's portfolio includes treatments for oncology, neuroscience, and rare diseases. Key products include Somatuline, used for neuroendocrine tumors and acromegaly; Dysport, a treatment for motor muscular disorders and medical aesthetics; and Cabometyx, targeting renal cell and second-line hepatocellular carcinoma. Ipsen generates revenue from product sales and licensing agreements, and it invests in research and development to expand its product pipeline. The company operates in a competitive landscape, facing competition from major pharmaceutical companies and smaller biotech firms.
What do analysts say about IPSEF stock?
Analyst consensus for IPSEF stock is mixed, with some analysts rating it as a hold and others as a buy. Key valuation metrics include a P/E ratio of 28.99 and a dividend yield of 0.90%. Growth considerations include the company's pipeline of new drugs, its expansion into emerging markets, and its strategic acquisitions. Analysts also note the risks associated with patent expirations and competition from generic drug manufacturers. The overall sentiment is cautiously optimistic, with analysts expecting moderate growth in revenue and earnings over the next few years.
What are the main risks for IPSEF?
The main risks for IPSEF include patent expirations on key products, increasing competition from generic drug manufacturers, pricing pressures from healthcare payers, regulatory setbacks or delays in drug approvals, and product liability claims and litigation. Patent expirations can lead to a significant decline in revenue as generic versions of Ipsen's products enter the market. Competition from generic drug manufacturers can also erode Ipsen's market share and profitability. Pricing pressures from healthcare payers can reduce the company's revenue and earnings. Regulatory setbacks or delays in drug approvals can delay or prevent the launch of new products. Product liability claims and litigation can result in significant financial losses.
What are the key factors to evaluate for IPSEF?
Ipsen S.A. (IPSEF) currently holds an AI score of 53/100, indicating moderate score. Key strength: Diversified product portfolio in specialty care. Primary risk to monitor: Patent expirations on key products leading to generic competition. This is not financial advice.
How frequently does IPSEF data refresh on this page?
IPSEF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven IPSEF's recent stock price performance?
Recent price movement in Ipsen S.A. (IPSEF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diversified product portfolio in specialty care. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider IPSEF overvalued or undervalued right now?
Determining whether Ipsen S.A. (IPSEF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying IPSEF?
Before investing in Ipsen S.A. (IPSEF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be delayed.
- OTC market data may be less reliable than exchange-listed data.